6 recruiting, 4 not yet recruiting. 4 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 2 |
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Muscle Invasive Bladder Cancer (MIBC): new trials by email Literature Review of Muscle Invasive Bladder Cancer (MIBC) trials Research Report on Muscle Invasive Bladder Cancer (MIBC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer) None. Registry. - Muscle Invasive Bladder Cancer (MIBC) | Not yet recruiting | Heinrich-Heine University, Duesseldorf | 100 | 2026-09-01 | 2026-08-04 | |
| Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) Perioperative Systemic Therapy Registry - Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC) | Recruiting | LMU Klinikum | 500 | 2026-05-17 | 2026-10-02 | |
| Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging Bladder Cancer, Urothelial Carcinoma (UC) | Recruiting | Oslo University Hospital | 150 | 2026-04-22 | 2026-05-22 | |
| Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | chenxu | 146 | 2026-03-26 | 2026-03-17 |
| Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment RC48-ADC combined with toripalimab for bladder-sparing therapy - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 59 | 2025-12-01 | 2025-10-01 |
| Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy Intravenous fluids, ERAS - Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC) | Not applicable | Recruiting | Johns Hopkins University | 130 | 2025-11-01 | 2025-11-20 |
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC Zanidatamab, Tislelizumab, Cisplatin - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 25 | 2025-10-25 | 2025-12-22 |
| MRI-Guided Bladder Preservation Program For Patients With Muscle Invasive Bladder Cancer MR-guided Radiation Therapy - Muscle Invasive Bladder Cancer (MIBC) | Not applicable | Not yet recruiting | Clinica Universidad de Navarra, Universidad de Navarra | 31 | 2025-10-01 | 2025-08-24 |
| Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment - Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy | Phase 3 | Recruiting | University of Rome Tor Vergata | 92 | 2025-08-15 | 2025-07-24 |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 - Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 / Phase 2 | Recruiting | Lumara Bio Oncologics GmbH | 270 | 2023-03-14 | 2026-08-11 |
Carcinoma, Transitional Cell (4) · Urinary Bladder Neoplasms (3) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Pathologic Complete Response (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (5) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Urinary Bladder Diseases (3) · Adenocarcinoma (1) · Breast Diseases (1)
toripalimab (2) · 130-nm albumin-bound paclitaxel (1) · Cisplatin (1) · Gemcitabine (1) · Multiparametric Magnetic Resonance Imaging (1) · Probiotics (1) · Transurethral Resection of Bladder (1) · disitamab vedotin (1) · tislelizumab (1) · zanidatamab (1)
Clinica Universidad de Navarra, Universidad de Navarra (1) · Fujian Medical University Union Hospital (1) · Heinrich-Heine University, Duesseldorf (1) · Johns Hopkins University (1) · LMU Klinikum (1) · Lumara Bio Oncologics GmbH (1) · Oslo University Hospital (1) · Qilu Hospital of Shandong University (1) · University of Rome Tor Vergata (1) · chenxu (1)
China (2) · Australia (1) · France (1) · Germany (1) · Italy (1) · Norway (1) · United States (1)
Andreas Habberstad, MD, PhD (1) · Max Kates, MD (1) · Simone Albisinni, MD, Phd, FEBU (1)
PMID 34740921, PMID 37988648, PMID 38940019
2023 (1)